Table 2.
Subgroup Analyses for Risk of Rebleeding, In-hospital Mortality, and That after Rebleeding, according to Age, Sex, Hemodialysis, and Antithrombotic Agent Status (Vonoprazan vs. Oral PPI).
| Rebleeding risk | In-hospital mortality risk | In-hospital mortality risk after rebleeding | ||||||
|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | OR | 95% CI | |||
| Vonoprazan vs. oral PPI | ||||||||
| Age (years) | p†=0.292 | p†=0.948 | p†=0.640 | |||||
| ≤64 | 0.98 | 0.85-1.13 | 0.97 | 0.74-1.28 | 1.25 | 0.67-2.35 | ||
| 65-74 | 1.07 | 0.94-1.21 | 0.80 | 0.62-1.04 | 1.07 | 0.58-2.00 | ||
| ≥75 | 1.08 | 0.98-1.20 | 0.95 | 0.77-1.17 | 1.02 | 0.60-1.74 | ||
| Sex | p†=0.180 | p†=0.504 | p†=0.588 | |||||
| Male | 1.09 | 0.99-1.19 | 0.88 | 0.74-1.04 | 1.02 | 0.67-1.56 | ||
| Female | 0.98 | 0.87-1.11 | 0.97 | 0.76-1.24 | 1.24 | 0.70-2.21 | ||
| Hemodialysis | p†=0.818 | p†=0.276 | p†=0.850 | |||||
| Yes | 1.09 | 0.80-1.49 | 0.64 | 0.33-1.23 | 1.24 | 0.33-4.63 | ||
| No | 1.05 | 0.98-1.13 | 0.93 | 0.33-1.09 | 1.08 | 0.76-1.54 | ||
| Antithrombotic agents | p†=0.750 | p†=0.030 | p†=0.201 | |||||
| Yes | 1.03 | 0.89-1.19 | 1.21 | 0.90-1.63 | 1.60 | 0.81-3.19 | ||
| No | 1.06 | 0.98-1.15 | 0.84 | 0.71-0.98 | 0.96 | 0.65-1.42 | ||
†p for interaction.
PPI: proton pump inhibitor, OR: odds ratio, CI: confidence interval